Alexza Initiates Second Phase III Study of Agitation Drug
Posted on: Friday, 25 July 2008, 12:01 CDT
Alexza Pharmaceuticals has initiated its second Phase III clinical trial with AZ-004, an inhalation product candidate being developed for the treatment of acute agitation in patients with schizophrenia or bipolar disorder.
The trial is an in-clinic, multi-center, randomized, double-blind, placebo-controlled study and will test AZ-004 at two dose levels, five and 10mg. Patients may receive up to three doses of study drug in a 24-hour period, depending on their clinical status. Patients eligible for the study include those who are admitted through an emergency department and those who are already in-patients in a hospital setting, as long as they have acute agitation at the time of patient randomization.
This study is said to be the first AZ-004 study enrolling bipolar disorder patients. Alexza projects that this second Phase III clinical trial will take approximately 12 months to complete patient enrollment.
The primary endpoint for the study is the change from baseline in the positive and negative symptom scale excited component score, measured at two hours after the first dose.
Various assessments of a patient's agitation state will be conducted at serial time points using standard agitation scales over the first four-hour post-dose time period, with follow-up assessments at the end of the 24-hour study period. Side effects will be recorded throughout the 24-hour period.
Alexza believes that the novel, non-invasive nature and rapid pharmacokinetic properties resulting from inhaled loxapine administration via the Staccato system have the potential to make AZ-004 a viable product to treat acute agitation.
AZ-004 is being developed through Symphony Allegro, a product development partnership formed between Alexza and Symphony Capital. The second AZ-004 Phase III clinical trial is designed to enroll approximately 300 patients diagnosed with bipolar I disorder and acute agitation at 18 US clinical centers.
Source: Datamonitor
Related Articles
- Algeta to Enroll US Patients Into Global Phase III ALSYMPCA Trial Following Successful End-of-Phase II Meeting With FDA
- Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
- AEterna Enters Second Stage of Patient Recruitment for Phase II Cancer Trial
- AEterna Enters Second Stage of Patient Recruitment for Phase II Cancer Trial
- EarlySense Receives FDA Clearance for Its Contact-Free Patient's Clinical Status Monitor
- MEDecision's Patient Clinical Summary To Be Implemented By Memphis Managed Care Corporation
- Alexza to Release Top-Line Results From AZ-001 Phase IIb and AZ-004 Phase IIa Clinical Trials
- Alexza Completes Enrollment in AZ-004 Phase IIa Clinical Trial in Schizophrenic Patients With Acute Agitation
- Clinics Cut Hours As Sex Diseases Rocket
- Studies Show Schizophrenia Patients Taking Atypicals Stayed on Treatment Longer Than Patients Taking Older, Typical Antipsychotics
 |
 |
User Comments (0)
RSS Feeds